Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
UNIGENE LABORATORIES INC (UGNE)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-13 | Dec-31-12 | Sep-30-12 | Jun-30-12 | Mar-31-12 | Dec-31-11 | Sep-30-11 | Jun-30-11 |
| | 10-Q | 10-K | 10-Q | 10-Q/A | 10-Q | 10-K | 10-Q | 10-Q/A |
| Revenues: |
| Product sales | | 0.4 | 2.0 | 1.3 | 0.6 | 1.3 | 1.3 | 0.6 |
| Licensing revenue | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 8.3 | 0.7 | 0.7 |
| Royalties | 0.1 | 0.0 | 0.2 | 0.1 | 0.3 | 0.4 | 0.3 | 0.4 |
| Other | 0.3 | 1.8 | 0.8 | 0.5 | 0.5 | 3.6 | 0.7 | 0.2 |
| Total revenues [+] | 0.6 | 2.5 | 3.3 | 2.2 | 1.8 | 13.5 | 3.0 | 2.0 |
| Licensing | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 8.3 | 0.7 | 0.7 |
| Royalties | 0.1 | 0.0 | 0.2 | 0.1 | 0.3 | 0.4 | 0.3 | 0.4 |
| Products | | 0.4 | 2.0 | 1.3 | 0.6 | 1.3 | 1.3 | 0.6 |
| Revenue growth [+] | -65.0% | -81.3% | 9.7% | 9.6% | -10.8% | 286.8% | 16.4% | -34.1% |
| Product sales | | -66.2% | 58.5% | 100.2% | -0.2% | -2.0% | 0.4% | -53.4% |
| Licensing revenue | 0.0% | -96.8% | -61.4% | -62.7% | -53.3% | 2189.2% | 117.5% | 125.5% |
| Royalties | -75.6% | -92.6% | -45.6% | -63.8% | -32.2% | -30.7% | -58.8% | -55.3% |
| Cost of goods sold | 1.6 | 0.1 | 0.8 | 0.5 | 0.2 | 0.5 | 0.5 | 0.3 |
| Gross profit | -1.0 | 2.4 | 2.5 | 1.7 | 1.5 | 13.0 | 2.5 | 1.7 |
| Gross margin | -166.5% | 95.6% | 74.8% | 79.3% | 85.9% | 96.1% | 83.6% | 86.4% |
| Selling, general and administrative | 2.0 | 1.9 | 2.4 | 2.2 | 2.1 | 2.1 | 2.1 | 2.3 |
| Research and development | 0.9 | 5.3 | | | 1.3 | 9.0 | | |
| Equity in earnings | | -0.7 | | | -0.7 | -2.8 | | |
| Other operating expenses | 0.5 | -1.9 | 1.7 | 1.5 | 0.8 | -5.3 | 3.5 | 2.5 |
| EBITDA [+] | -4.7 | -5.6 | -2.1 | | -3.4 | -5.8 | -3.5 | |
| EBITDA growth | 35.8% | -3.2% | -40.1% | -36.9% | -5.4% | 106.4% | 58.9% | -3.5% |
| EBITDA margin | -760.3% | -222.6% | -63.4% | -88.6% | -196.2% | -43.0% | -116.2% | -153.8% |
| Depreciation | -0.3 | -2.1 | -0.4 | | -0.2 | -10.2 | -0.3 | |
| EBITA | -4.3 | -3.5 | -1.7 | -1.9 | -3.3 | 4.4 | -3.1 | -3.1 |
| EBITA margin | -707.6% | -138.4% | -51.2% | -88.6% | -187.0% | 32.6% | -104.6% | -153.8% |
| Amortization of intangibles | 0.0 | 0.0 | | | 0.0 | 0.0 | | |
| EBIT [+] | -4.4 | -3.5 | -1.7 | -1.9 | -3.3 | 4.4 | -3.1 | -3.1 |
| EBIT growth | 32.6% | -180.7% | -46.3% | -36.9% | -9.1% | -278.0% | 71.2% | 2.3% |
| EBIT margin | -713.1% | -139.6% | -51.2% | -88.6% | -188.5% | 32.3% | -104.6% | -153.8% |
| Non-recurring items [+] | 1.0 | 0.2 | | | 0.1 | 0.8 | | |
| Asset impairment | 1.0 | 0.1 | | | 0.1 | | | |
| Interest expense, net [+] | 4.5 | 4.2 | 3.5 | 3.3 | 2.8 | 2.5 | 2.8 | 2.7 |
| Interest expense | 4.5 | 4.2 | 3.5 | 3.3 | 2.9 | 2.5 | 2.8 | 2.7 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net | 11.9 | -15.0 | 0.6 | -6.0 | 2.9 | 25.3 | 2.3 | 8.1 |
| Pre-tax income | 2.0 | -22.9 | -4.5 | -11.2 | -3.2 | 26.3 | -3.6 | 2.3 |
| Income taxes | 0.0 | -1.2 | 0.0 | 0.0 | 0.0 | -0.6 | 0.0 | 0.0 |
| Tax rate | 0.0% | 5.4% | 0.0% | 0.0% | 0.8% | | 0.0% | 0.0% |
| Net income | 2.0 | -34.3 | 0.0 | 0.0 | -3.2 | -7.1 | 0.0 | 0.0 |
| Net margin | 322.4% | -1352.7% | 0.0% | 0.0% | -182.5% | -52.4% | 0.0% | 0.0% |
| |
| Basic EPS [+] | $0.02 | ($0.36) | $0.00 | $0.00 | ($0.03) | ($0.08) | $0.00 | $0.00 |
| Growth | -161.5% | 371.7% | | | | -78.5% | | |
| Diluted EPS [+] | $0.00 | ($0.36) | $0.00 | $0.00 | ($0.03) | ($0.08) | $0.00 | $0.00 |
| Growth | -111.6% | 371.7% | | | | -78.5% | | |
| |
| Shares outstanding (basic) [+] | 96.0 | 95.5 | 95.5 | 95.4 | 95.3 | 93.2 | 92.9 | 92.5 |
| Growth | 0.7% | 2.4% | 2.8% | 3.1% | 3.1% | 1.3% | 0.9% | -100.0% |
| Shares outstanding (diluted) [+] | 508.0 | 95.5 | 95.5 | 95.4 | 95.3 | 93.2 | 92.9 | 95.2 |
| Growth | 433.0% | 2.4% | 2.8% | 0.2% | 3.1% | 1.3% | 0.9% | -100.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|